Login / Signup

Systemic, local, and sclerotherapy drugs: What do we know about drug prescribing in vascular anomalies?

Simon MarcouxYves TheoretJosée DuboisSandrine EssouriAlix PincivyJerome CoulombeCatherine C McCuaigJulie PowellGilles SoulezNiina Kleiber
Published in: Pediatric blood & cancer (2021)
Off-label drug prescribing, frequent in the treatment of vascular anomalies (VA), relies on the quality of the literature reporting drug efficacy and safety. Our objective is to review the level of evidence (LOE) surrounding drug use in VA, which is more prevalent in pediatric care. A list of drugs used in VA was created with a literature review in July 2020. For each drug listed, the article displaying the highest LOE was determined and then compared between efficacy/safety data, routes of administration, pharmacological categories and a subset of VA. The influence of research quality on study results was also explored. The median LOE for the 74 drugs identified poor methodological quality, with a predominance of retrospective studies or case reports. Drug safety is currently inadequately reported. This is alarming as many treatments display significant safety concerns. Also, current literature displays major publication bias that probably leads to overestimation of drug efficacy in VA.
Keyphrases
  • adverse drug
  • drug induced
  • primary care
  • systematic review
  • healthcare
  • quality improvement
  • case report
  • emergency department
  • palliative care
  • deep learning
  • health insurance